Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics to Present Preclinical Data at AACR Meeting
BOTHELL, Wash., Apr 8, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report preclinical data describing the progress of certain of its monoclonal antibody-based therapeutics during the 93rd Annual Meeting of the American Association of Cancer Research
View HTML
Toggle Summary Seattle Genetics Names CEO as Chairman and Appoints General Counsel
BOTHELL, Wash., Apr 1, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that H. Perry Fell, Ph.D. has been appointed as the Company's Chairman of the Board. Dr. Fell co-founded Seattle Genetics and serves as Chief Executive Officer.
View HTML
Toggle Summary Celltech and Seattle Genetics Announce Antibody-Drug Conjugate Collaboration
SLOUGH, England, and BOTHELL, Wash., Mar 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Celltech Group plc (LSE: CCH; NYSE: CLL) and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced a multi-target collaboration to use Seattle Genetics' antibody-drug conjugate technology with Celltech's antibody
View HTML
Toggle Summary Seattle Genetics Initiates Phase I Clinical Trial with Monoclonal Antibody SGN-30
BOTHELL, Wash., Mar 21, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the initiation of its first phase I clinical trial with the therapeutic monoclonal antibody SGN-30 for the treatment of hematologic malignancies. The single agent study is designed as a rapid dose
View HTML
Toggle Summary Seattle Genetics Licenses Monoclonal Antibodies from Mabtech AB
BOTHELL, Wash., Mar 14, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has entered into an agreement to license certain monoclonal antibodies from Mabtech AB, located in Sweden. The agreement includes multiple antibodies that target cell surface molecules on a
View HTML
Toggle Summary Seattle Genetics Reports Fourth Quarter and Year 2001 Results
BOTHELL, Wash., Jan 31, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) today reported results for its fourth quarter and year ended December 31, 2001. Revenues for the fourth quarter of 2001 were $169,000, up from revenues of $16,000 in the fourth quarter of 2000.
View HTML
Toggle Summary Seattle Genetics Announces That Its Anti-CD40 Monoclonal Antibody Enters Clinical Development At Genentech
BOTHELL, Wash., Jan 8, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that its anti-CD40 monoclonal antibody (mAb) has entered the Genentech, Inc. (NYSE:DNA) clinical development portfolio. The product candidate, PRO64553, is a humanized mAb targeted to CD40 and is
View HTML
Toggle Summary Genencor and Seattle Genetics Announce Collaboration To Advance Targeted Cancer Therapies
Lead Product Candidate for Metastatic Melanoma Will Be Developed Jointly PALO ALTO, Calif. and BOTHELL, Wash., Jan 7, 2002 /PRNewswire via COMTEX/ -- Genencor International, Inc. (Nasdaq: GCOR) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that they have formed a strategic alliance to
View HTML
Toggle Summary Seattle Genetics Appoints New Member to its Scientific Advisory Board
BOTHELL, Wash., Jan 4, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the appointment of Bruce R. Blazar, M.D. to its Scientific Advisory Board. Dr. Blazar is a Professor in the Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplant
View HTML
Toggle Summary Seattle Genetics Scheduled to Present at JPMorgan H&Q Healthcare Conference
BOTHELL, Wash., Jan 3, 2002 (BW HealthWire) -- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that H. Perry Fell, Ph.D., Chief Executive Officer and Clay B. Siegall, Ph.D., President and Chief Scientific Officer, will speak at the JPMorgan H&Q 20th Annual Healthcare Conference on Tuesday,
View HTML